DekaBank Deutsche Girozentrale Takes $1.29 Million Position in Alkermes plc (NASDAQ:ALKS)

DekaBank Deutsche Girozentrale bought a new position in shares of Alkermes plc (NASDAQ:ALKS) in the 2nd quarter, Holdings Channel reports. The fund bought 53,517 shares of the company’s stock, valued at approximately $1,285,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Signaturefd LLC boosted its position in shares of Alkermes by 51.2% in the second quarter. Signaturefd LLC now owns 1,417 shares of the company’s stock valued at $34,000 after acquiring an additional 480 shares during the period. Hexagon Capital Partners LLC grew its position in shares of Alkermes by 3,841.0% during the 2nd quarter. Hexagon Capital Partners LLC now owns 1,537 shares of the company’s stock worth $37,000 after purchasing an additional 1,498 shares in the last quarter. GAMMA Investing LLC increased its holdings in shares of Alkermes by 44.4% during the second quarter. GAMMA Investing LLC now owns 2,287 shares of the company’s stock worth $55,000 after purchasing an additional 703 shares during the period. CWM LLC raised its position in shares of Alkermes by 36.7% in the first quarter. CWM LLC now owns 2,732 shares of the company’s stock valued at $74,000 after buying an additional 733 shares in the last quarter. Finally, Ashton Thomas Private Wealth LLC bought a new stake in shares of Alkermes in the second quarter valued at approximately $116,000. Institutional investors and hedge funds own 95.21% of the company’s stock.

Alkermes Stock Up 1.9 %

Shares of ALKS opened at $28.35 on Friday. The stock has a market capitalization of $4.80 billion, a price-to-earnings ratio of 11.21, a PEG ratio of 0.56 and a beta of 0.46. Alkermes plc has a 52 week low of $22.01 and a 52 week high of $32.88. The company has a debt-to-equity ratio of 0.22, a quick ratio of 2.61 and a current ratio of 2.99. The stock has a fifty day moving average of $27.00 and a 200-day moving average of $25.86.

Alkermes (NASDAQ:ALKS) last announced its quarterly earnings results on Wednesday, July 24th. The company reported $0.70 EPS for the quarter, meeting analysts’ consensus estimates of $0.70. Alkermes had a return on equity of 23.20% and a net margin of 19.15%. The firm had revenue of $399.13 million for the quarter, compared to analyst estimates of $393.30 million. During the same period last year, the firm posted $0.38 earnings per share. The business’s revenue for the quarter was down 35.4% on a year-over-year basis. As a group, sell-side analysts anticipate that Alkermes plc will post 2.36 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms have commented on ALKS. TD Cowen initiated coverage on Alkermes in a research note on Monday, June 17th. They set a “buy” rating and a $34.00 price objective on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $48.00 price target on shares of Alkermes in a research note on Monday. Robert W. Baird increased their price objective on shares of Alkermes from $37.00 to $38.00 and gave the stock an “outperform” rating in a research note on Thursday, July 25th. HC Wainwright raised their target price on shares of Alkermes from $35.00 to $37.00 and gave the company a “neutral” rating in a report on Thursday, July 25th. Finally, JPMorgan Chase & Co. upped their price target on shares of Alkermes from $31.00 to $32.00 and gave the stock a “neutral” rating in a report on Thursday, July 25th. One analyst has rated the stock with a sell rating, three have issued a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Alkermes currently has a consensus rating of “Moderate Buy” and an average target price of $36.70.

About Alkermes

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.